Axsome Therapeutics, Inc. 0HKF.L
0HKF.L
Axsome Therapeutics, Inc. 0VGI.L
TG Therapeutics, Inc. 0HI3.L
Arrowhead Pharmaceuticals, Inc. 0VQA.L
Viking Therapeutics, Inc. 0I3Q.L
Corcept Therapeutics Incorporated 0J2O.L
Halozyme Therapeutics, Inc. 0Y5E.L
Perrigo Company plc 0EE0.L
uniQure N.V. 0JBU.L
Intellia Therapeutics, Inc. 0LB2.L
Supernus Pharmaceuticals, Inc.
Axsome Therapeutics, Inc. 0VGI.L
TG Therapeutics, Inc. 0HI3.L
Arrowhead Pharmaceuticals, Inc. 0VQA.L
Viking Therapeutics, Inc. 0I3Q.L
Corcept Therapeutics Incorporated 0J2O.L
Halozyme Therapeutics, Inc. 0Y5E.L
Perrigo Company plc 0EE0.L
uniQure N.V. 0JBU.L
Intellia Therapeutics, Inc. 0LB2.L
Supernus Pharmaceuticals, Inc.
Performance
| Periode | 0HKF.L | 0VGI.L | 0HI3.L | 0VQA.L | 0I3Q.L | 0J2O.L | 0Y5E.L | 0EE0.L | 0JBU.L | 0LB2.L |
|---|---|---|---|---|---|---|---|---|---|---|
| 6M | 23.01 % | 32.21 % | 205.35 % | 36.93 % | 3.18 % | 9.00 % | -13.81 % | 347.79 % | 90.75 % | 66.61 % |
| YTD | 46.70 % | 19.60 % | 101.90 % | -17.04 % | 46.99 % | 35.03 % | -17.69 % | 250.99 % | 28.64 % | 46.89 % |
| 1Y | 44.46 % | 53.67 % | 93.47 % | -54.88 % | 50.62 % | 30.36 % | -15.50 % | 831.53 % | -4.80 % | 55.00 % |
| 3Y | 206.40 % | 577.21 % | 18.39 % | 691.04 % | 143.48 % | 36.49 % | -35.15 % | 237.80 % | -70.62 % | 53.79 % |
| 5Y | 3 813.69 % | 207.56 % | -47.68 % | 446.43 % | 326.02 % | 51.24 % | -35.15 % | 49.12 % | -83.82 % | 143.83 % |
| 10Y | 3 813.69 % | 207.56 % | 527.23 % | 132.86 % | 191.94 % | 247.99 % | -35.15 % | 229.09 % | -83.82 % | 28.71 % |
| From the beginning | 3 813.69 % | 207.56 % | 527.23 % | 132.86 % | 191.94 % | 247.99 % | -35.15 % | 229.09 % | -83.82 % | 28.71 % |